Target
$218.56 → $217.97
Current stock research snapshot · 7/10/26 47 days old
NTRANatera
Investment conviction●●○○○2 of 5 · current snapshot
Research target$217.97Current stock price target
Investment thesis statusSTRENGTHENEDLast reviewed 7/10/26
Market cap$38.66BSnapshot value · 7/10/26
Research history
See all NTRA changes ↗What changed
Target
$218.68 → $218.56
Genetic testing + MRD pure-play. Signatera (MRD) and Panorama (NIPT) drive recurring test-volume revenue. High growth but negative earnings.
Q1 2026 >1M tests processed; FY2026 revenue guide raised to $2.74B-$2.82B; continued Signatera and Fetal Focus adoption; payer coverage / label expansion.
Thesis weakens if reimbursement stalls, Signatera adoption decelerates, or competition compresses price / margin leverage before durable cash generation arrives.
bullish; X discussion centered on Signatera adoption, FY26 guidance raise, and first-quarter volume strength
Snapshot · 7/10/26🟡 Mixed · ins-$7.0M · 13F 17+/7-×0.5 · short↑0.35
Snapshot · 7/10/26Timestamped research update
Deep research update
827 words · Updated Aug 2, 2026
Research in development: this latest 827-word update is published for context while it is expanded toward the 1,000-word editorial standard.
Natera is a cell-free DNA (cfDNA) diagnostics company whose moat rests on tumor-informed minimal residual disease (MRD) testing. Signatera — its flagship — creates a personalized 16-SNV assay from each patient's tumor tissue, then tracks those mutations in blood to detect recurrence months before imaging. Portfolio also includes Panorama (NIPT prenatal screening), Horizon (hereditary cancer), and Prospera (organ transplant rejection).
FY2025 revenue $2,306M (+36.6% YoY per SEC XBRL). Q1 2026 revenue $696.6M (+38.8% YoY). Gross margin 64.7% Q1 2026. Operating margin still negative: FY2025 R&D $624M (27.1% of rev), SG&A $1,177M (51.0%), net loss -$208M. Q1 2026 net loss narrowed to -$85.1M. Market cap ~$38.4B, enterprise value ~$37.5B. Q1 2026 processed >1M tests for first time. FY2026 revenue guidance raised to $2.74B-$2.82B.
Signatera is a recurring-revenue diagnostic embedding itself into oncology surveillance pathways. Every new patient generates a personalized assay — once embedded, switching costs lock in test volume for years of monitoring. Revenue compounds as (a) oncologist adoption grows, (b) payer coverage expands across solid tumor types, and (c) monitoring duration lengthens.
- Q1 2026 revenue $696.6M (+38.8% YoY); FY2026 guidance $2.74B-$2.82B implies 19-22% YoY growth at midpoint. Source: SEC 10-Q EX-99.1
- >1M tests processed in a single quarter for the first time (Q1 2026). Source: SEC 10-Q EX-99.1
- FY2025 R&D spend $624M (27.1% of rev), SG&A $1,177M (51.0% of rev) — the business is still scaling its commercial engine. Source: SEC XBRL companyfacts CIK 0001604821
- Q1 2026 positive cash inflow ~$11.8M — first sign of operating leverage. Source: Q1 2026 8-K EX-99.1
- Heavy insider selling: 7 Form 4s and 8 Form 144s filed July 28-29, 2026 — pre-planned 10b5-1 or discretionary? Needs classification. Source: SEC EDGAR filings index
- Guardant Health's Reveal (tumor-naive MRD) competes on workflow simplicity (no tumor sample needed) but with lower sensitivity — structural trade-off between the two approaches. Source: SEC 10-K risk factors + competitive positioning
- FY2025 annual revenue $2,306M vs FY2024 $1,688M (+36.6%); quarterly progression Q1→Q4: $502M→$547M→$592M→$666M — clean sequential acceleration throughout 2025. Source: SEC XBRL
The personalized tumor-informed assay is the structural moat. Signatera sequences the patient's own tumor to create a bespoke 16-SNV panel. This creates a biological switching cost: moving to a competitor's assay means re-biopsying (if tissue still available) or re-sequencing archival tissue — $1,000-2,000 per patient in direct costs, plus 2-4 weeks turnaround time during which monitoring is interrupted. For a 500-patient oncology practice at $3,500/test × 4 tests/year = $7M annual spend, the switching cost is $650K-$1.45M (9-21% of annual spend) in patient re-sequencing + IT integration + clinician retraining. For a 5,000-patient academic medical center, it's $5.5M-$12M (8-17% of annual spend). This is high enough to deter casual switching but not insurmountable — the real lock-in is oncologist habit and payer contract integration.
- Guardant Reveal (tumor-naive) wins on workflow simplicity — no tumor tissue needed, faster time-to-first-result. If sensitivity gap narrows below clinical significance threshold, the personalized assay moat erodes.
- Heavy July 28-29 insider selling (7 Form 4s, 8 Form 144s) — if not 10b5-1 pre-planned, this is a negative signal at $38B market cap with -$85M quarterly net loss.
- $38.4B market cap on $2.3B revenue (+37% growth) = 16.7× trailing P/S. Valuation embeds continued 30%+ growth and eventual GAAP profitability. Any growth deceleration below 25% YoY would compress the multiple.
- Reimbursement risk: MolDX pricing and private payer coverage decisions are binary events. A single adverse coverage determination (e.g., colorectal cancer surveillance) would remove a whole indication.
- Competition from Exact Sciences (Oncotype + MRD pipeline), Foundation Medicine (Roche), and potential new entrants with lower-cost sequencing.
- Stock-based compensation dilution: FY2025 SBC likely material given tech-bio comp structure.
- Were the July 28-29 Form 4 sales 10b5-1 pre-planned or discretionary? The volume (15+ filings in 2 days) suggests coordinated plan, but needs verification.
- Q2 2026 earnings (due by Aug 14): can revenue accelerate beyond Q1's 38.8% pace? Is Q1's $11.8M positive cash flow sustainable or one-time?
- What is Signatera revenue specifically (vs Panorama/Horizon/Prospera)? Product-level disclosure would reveal whether the MRD moat is driving growth or if prenatal is still the revenue engine.
- How much of the ~27% R&D-to-revenue ratio is sustaining vs. growth investment? If growth R&D can be scaled back, the path to GAAP profitability is clearer.
- What is the Signatera volume split between colorectal cancer (most mature indication) vs newer indications (breast, lung, bladder)? Diversification across tumor types reduces single-indication reimbursement risk.
INTACT — thesis strengthened by Q1 2026 revenue acceleration and first positive cash flow, but $38B valuation prices in continued perfection. Heavy insider selling on July 28-29 needs classification before conviction can increase.